Tolga Tanguler insider trades: Alnylam Pharmaceuticals (ALNY) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Tolga reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | ALNY | ↓ Sell | 2,309 | $323.08 | $746K | Direct | Mar 6, 2026 (2d) |
| Mar 2, 2026 | ALNY | ↓ Sell | 1,598 | $327.65 | $524K | Direct | Mar 4, 2026 (2d) |
| Feb 13, 2026 | ALNY | ↓ Sell | 1,959 | $310.08 | $607K | Direct | Feb 17, 2026 (4d) |
| Jan 12, 2026 | ALNY | ↓ Sell | 1,510 | $362.87 | $548K | Direct | Jan 14, 2026 (2d) |
| Oct 2, 2025 | ALNY | ↓ Sell | 1,405 | $452.05 | $635K | Direct | Oct 3, 2025 (1d) |
| Aug 29, 2025 | ALNY | ↓ Sell | 3,474 | $448.37 | $1.6M | Direct | Sep 2, 2025 (4d) |
| Aug 18, 2025 | ALNY | ↓ Sell | 1,396 | $453.27 | $633K | Direct | Aug 19, 2025 (1d) |
| Mar 3, 2025 | ALNY | ↓ Sell | 471 | $243.78 | $115K | Direct | Mar 5, 2025 (2d) |
| Feb 28, 2025 | ALNY | ↓ Sell | 513 | $241.68 | $124K | Direct | Mar 3, 2025 (3d) |
| Nov 26, 2024 | ALNY | ↓ Sell | 1,469 | $250.98 | $369K | Direct | Nov 27, 2024 (1d) |
| Jun 25, 2024 | ALNY | ↓ Sell | 1,605 | $231.00 | $371K | Direct | Jun 26, 2024 (1d) |
| Feb 28, 2024 | ALNY | ↓ Sell | 501 | $155.30 | $78K | Direct | Feb 29, 2024 (1d) |
| Feb 16, 2024 | ALNY | ↓ Sell | 1,009 | $148.06 | $149K | Direct | Feb 20, 2024 (4d) |
| Apr 27, 2023 | ALNY | ↓ Sell | 1,476 | $194.59 | $287K | Direct | Apr 28, 2023 (1d) |
| Feb 3, 2023 | ALNY | ↓ Sell | 5,025 | $230.19 | $1.2M | Direct | Feb 3, 2023 (0d) |
| Aug 5, 2022 | ALNY | ↓ Sell | 3,595 | $214.18 | $770K | Direct | Aug 5, 2022 (0d) |
| Jul 5, 2022 | ALNY | ↓ Sell | 1,754 | $150.00 | $263K | Direct | Jul 7, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ALNY insiders
Open-market trades in the last 12 months
About Tolga Tanguler's insider trades
Tolga Tanguler is EVP, Chief Commercial Officer at Alnylam Pharmaceuticals (ALNY). Since Jul 5, 2022, Tolga has reported no open-market purchases and 17 sales worth $8.9M on SEC Form 4. In the last 12 months: 4 sales ($2.4M).
Their filings also include grants and awards (17 filings), option exercises (5 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALNY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.